secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2022-04-22T23:59:59+00:00
Accession:  0001297184-22-000021
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar subsidiary enters contract manufacturing deal with related party Hanxin for Chinese market
--------------------------------------------------------------------------------

- ANP will manufacture APIs and finished products on cost-plus basis for Hanxin, which will file for Chinese marketing authorizations.
- Hanxin, majority-owned by Drs. Zhang, Luo and family, is a related party; deal approved by independent disinterested directors.
- Hanxin commits to minimum purchase quantities under the agreement dated April 19, 2022; material terms to be filed with Q2 2022 10-Q.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718422000021/0001297184-22-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718422000021/amph-20220419x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-22-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer